4//SEC Filing
DAMME LAURA 4
Accession 0000899243-22-038829
CIK 0001756262other
Filed
Dec 15, 7:00 PM ET
Accepted
Dec 16, 4:30 PM ET
Size
20.3 KB
Accession
0000899243-22-038829
Insider Transaction Report
Form 4
DAMME LAURA
VP, Clinical Affairs
Transactions
- Exercise/Conversion
Common Stock
2022-12-14$38.46/sh+5,947$228,722→ 5,947 total - Sale
Common Stock
2022-12-15$58.96/sh−4,740$279,470→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-12-15−4,740→ 14,063 totalExercise: $38.46Exp: 2031-02-24→ Common Stock (4,740 underlying) - Exercise/Conversion
Common Stock
2022-12-15$38.46/sh+250$9,615→ 250 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-12-14−5,947→ 19,053 totalExercise: $38.46Exp: 2031-02-24→ Common Stock (5,947 underlying) - Sale
Common Stock
2022-12-14$62.43/sh−5,947$371,271→ 0 total - Sale
Common Stock
2022-12-15$60.02/sh−250$15,005→ 0 total - Exercise/Conversion
Common Stock
2022-12-15$38.46/sh+4,740$182,300→ 4,740 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-12-15−250→ 18,803 totalExercise: $38.46Exp: 2031-02-24→ Common Stock (250 underlying)
Footnotes (4)
- [F1]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $62.00 to $62.91, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $60.00 to $60.35, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $58.92 to $59.32, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021.
Documents
Issuer
TransMedics Group, Inc.
CIK 0001756262
Entity typeother
Related Parties
1- filerCIK 0001784433
Filing Metadata
- Form type
- 4
- Filed
- Dec 15, 7:00 PM ET
- Accepted
- Dec 16, 4:30 PM ET
- Size
- 20.3 KB